[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558754":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":67,"collaborators":26,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":26,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Medical University of Warsaw","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Trametynib","EXPERIMENTAL","Trametynib in 0,025mg\u002Fkg dose orally once daily",[13],"Drug: Trametinib tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard therapy","ACTIVE_COMPARATOR","Disopiramide and Beta-blocker orally",[19],"Drug: Standard therapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Trametinib tablet","Trametynib orally once daily in 0,025mg\u002Fkg dose",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Disopiramide and Beta blockers orally",[15],[31],{"name":32,"affiliation":5,"role":33},"MAciej Kołodziej, MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Maciej Kołodziej, MD","CONTACT","22-317-95-37","maciej.kolodziej@wum.edu.pl",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Halszka Kamińska, MD","22-317-9444","halszka.kaminska@wum.edu.pl",[45],{"facility":46,"status":47,"city":48,"state":26,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Department of Paediatrics, The Medical University of Warsaw, Poland","RECRUITING","Warsaw","02-091","Poland","PL",{"type":53,"coordinates":54},"Point",[55,56],21.01178,52.22977,{"lat":56,"lon":55},[59,62,63,64],{"name":36,"role":37,"phone":60,"phoneExt":26,"email":61},"223179535","maciek.kolodziej@gmail.com",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},{"name":36,"role":33,"phone":26,"phoneExt":26,"email":26},{"name":65,"role":66,"phone":26,"phoneExt":26,"email":26},"Hlaszka Kamińskia, MD","SUB_INVESTIGATOR",{"type":68,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100558754","phase-2-mek-inhibitors-for-the-treatment-of-hypertrophic-cardiomyopathy-in-patients-with-rasopathies-100558754",false,"NCT06555237","MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies","MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies (MEKinRAS) - Randomized Controlled Trial","MEKinRAS","Inclusion Criteria:\n\n* patient with diagnosed RASopathy\n* patient with diagnosed hypertrophic cardiomyopathy\n* signed innform consent\n\nExclusion Criteria:\n\n* contraindications to treatment with propranolol (drug hypersensitivity, atrioventricular block, severe bradycardia) disopyramide (drug hypersensitivity, WPW syndrome, atrioventricular block, QT prolongation) trametinib (drug hypersensitivity)\n* lack of consent of the child's guardians to participate in the study","ALL","1 Day","18 Years",{"count":81,"type":82},40,"ESTIMATED","INTERVENTIONAL",[85],"PHASE2","The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS\u002FMAPK pathway.",[88,89],"Cardiomegaly","Noonan Syndrome",[91,92,93,94,95],"Noonan syndrome","MEK kinase","RASOpathies","Children","Cardiomyopathy","2024-08-12",{"date":98,"type":99},"2024-08-15","ACTUAL",{"date":101,"type":99},"2024-08-01",{"date":103,"type":82},"2026-12-01",{"name":5,"class":6},1]